Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly
- PMID: 832074
- PMCID: PMC1604447
- DOI: 10.1136/bmj.1.6055.200
Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly
Abstract
Antibody responses to subunit influenza vaccine prepared against A2/England/42/72 (h3n2) were studied in 69 volunteers aged 60 and over and 231 aged 59 and below over 12 months in 1973 and 1974. After two doses of vaccine seroconversion frequencies and geometric mean haemagglutination-inhibition (HI) titres were higher in the elderly, but no differences were observed between the two groups in the length of their responses. Sixteen (23%) of the elderly volunteers seroconverted only after receiving a second dose of vaccine or seroconverted twice after receiving both doses of vaccine. It was considered justifiable, therefore, to recommend the continuation of a two-dose schedule for patients in a high-risk category. Within 30 weeks of vaccination 87 (29%) volunteers had considerably reduced HI titres (less than 48), which might indicate potential susceptibility to influenza during an epidemic, and the number had risen to 132 (44%) by 50 weeks. It was suggested that high-risk patients should receive annnual vaccination two to four months before the possible epidemic period.
Similar articles
-
A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.J Hyg (Lond). 1984 Jun;92(3):263-76. doi: 10.1017/s0022172400064500. J Hyg (Lond). 1984. PMID: 6736638 Free PMC article.
-
Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population.Vaccine. 1984 Mar;2(1):100-6. doi: 10.1016/s0264-410x(98)90040-8. Vaccine. 1984. PMID: 6531951 Clinical Trial.
-
Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.Gerontology. 2007;53(6):411-8. doi: 10.1159/000110579. Epub 2007 Oct 31. Gerontology. 2007. PMID: 17975317
-
Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20. Vaccine. 2012. PMID: 22192847 Clinical Trial.
-
Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.Pediatrics. 2006 Sep;118(3):e579-85. doi: 10.1542/peds.2006-0201. Pediatrics. 2006. PMID: 16950949 Clinical Trial.
Cited by
-
Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.J Clin Microbiol. 1989 Dec;27(12):2666-71. doi: 10.1128/jcm.27.12.2666-2671.1989. J Clin Microbiol. 1989. PMID: 2592535 Free PMC article.
-
Drug delivery issues in vaccine development.Pharm Res. 1996 Dec;13(12):1777-85. doi: 10.1023/a:1016064504346. Pharm Res. 1996. PMID: 8987071 Review.
-
Immunization of elderly volunteers with the 1988-89 inactivated whole influenza vaccine: assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests.Eur J Epidemiol. 1992 Jul;8(4):491-7. doi: 10.1007/BF00146365. Eur J Epidemiol. 1992. PMID: 1397214
-
Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults.BMC Infect Dis. 2015 Apr 23;15:195. doi: 10.1186/s12879-015-0926-8. BMC Infect Dis. 2015. PMID: 25903659 Free PMC article.
-
In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.J Clin Microbiol. 1991 Mar;29(3):498-505. doi: 10.1128/jcm.29.3.498-505.1991. J Clin Microbiol. 1991. PMID: 2037667 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical